Study identifier:D5890C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An 8-week, randomised, double blind, parallel-group, multi-centre, phase III study comparing the efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg twice daily and Pulmicort® Turbuhaler® 200 µg twice daily + Theolong® tablet 200 mg twice daily in Japanese patients with asthma
asthma
Phase 3
No
Budesonide/Formoterol, Budesonide, Theophylline
All
340
Interventional
16 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|